Ten‐year functional and oncological outcomes of a prospective randomized controlled trial comparing laparoscopic versus robot‐assisted radical prostatectomy

Abstract

BackgroundAmong prostate cancer (PCa) treatment options, mini‐invasive surgical approaches have gained a wide diffusion in the last decades. The aim of this study was to present oncological, functional, and quality of life data after 10 years of follow‐up of a prospective randomized controlled trial (RCT) (ISRCTN11552140) comparing robot‐assisted radical prostatectomy (RARP) versus laparoscopic radical prostatectomy (LRP) for the treatment of PCa.MethodsPatients with localized PCa were randomized to undergo LRP or RARP between January 2010 and January 2011. Functional (continence and potency) and oncological (prostate‐specific antigen, biochemical recurrence [BCR] and BCR‐free survival [BCRFS]) variables were evaluated. BCRFS curves were estimated by the Kaplan–Meier method and compared using the log‐rank test. Machine learning partial least square‐discriminant analysis (PLS‐DA) was used to identify the variables characterizing more the patients who underwent RARP or LRP.ResultsSeventy‐five of the originally enrolled 120 patients remained on follow‐up for 10 years; 40 (53%) underwent RARP and 35 (47%) LRP. Continence and potency recovery rates did not show significant differences (p = 0.068 and p = 0.56, respectively), despite a Δ12% for continence and Δ8% for potency in favor of the robotic approach. However, the quality of continence (in terms of International Consultation on Incontinence Questionnaire‐Short Form [ICIQ‐SF] score) and erection (in terms of International Index of Erectile Function‐5 [IIEF‐5] score) was significantly better after 10 years in the robotic group (p = 0.02 and p < 0.001). PLS‐DA revealed that LRP was characterized by the worst functional‐related outcomes analyzing the entire follow‐up period. Four (10%) and six (17%) patients experienced BCR in RARP and LRP groups, respectively (p = 0.36), with an overall 10‐year BCR‐free survival of 88% and 78% (p = 0.16).ConclusionsComparable continence and potency rates were observed between RARP and LRP after a 10‐year follow‐up. However, the RARP group exhibited superior totally dry rate and erection quality. No difference in terms of oncological outcomes was found.